Industry Bulletins | June 20, 2018
Dr.Reddy’s To Sell Generic Version Of Opioid Addiction Treatment Suboxone In U.S.
Dr.Reddy’s Laboratories (DRL) recently announced that its generic version of Indivior Plc’s Suboxone has received approval from the U.S. Food and Drug Administration (FDA). As a result, the company’s buprenorphine and naloxone sublingual film will be introduced to the U.S. market, pending an approved risk evaluation and mitigation strategy program.
Resulting from the announcement, DRL’s stock has surged, bringing in its highest close in more than four months. Additionally, Indivior’s own stock plunged more than 20%, as its Suboxone treatment represents about 80% of the company’s revenue. DRL’s new treatment . . .